| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 33.5 | 35.4 | 22.2 |
| Other income | 6.1 | 10.1 | 4.3 |
| Total income | 39.6 | 45.6 | 26.6 |
| Profit before exceptional items & tax | 13.2 | 14.6 | 15.9 |
| Profit before tax | 13.2 | 14.6 | 15.9 |
| Net profit | 9.0 | 9.8 | 12.6 |
| Operating margin | 33.3% | 32.0% | 59.8% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -28.60% |
|---|---|
| Net profit, quarter on quarter | -8.20% |
| Revenue, year on year | +50.90% |
| Operating profit, year on year | -38.80% |
| Operating profit, quarter on quarter | +57.80% |
BSE results filing, BSE: 532067. Figures extracted from the filing.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,576.20
- Market cap
- ₹1,353 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹58.59 Cr
- P/E (TTM)
- 24.4×Sector 37.2×
- Promoter holding
- 40.95%+0.01% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B BlackBio Dx Other Announcement
3B Blackbio Dx Limited has appointed M/s. Sanjay Kasliwal & Associates as the Cost Auditor for the company.
3B BlackBio Dx Investor Presentation: Key Takeaways
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
- Call
- Guides 18% growth
3B BlackBio Dx Board Meeting Date
3B BlackBio Dx Ltd has scheduled a board meeting for August 13, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.